钠-葡萄糖协同转运蛋白-2抑制剂在射血分数保留性心力衰竭中的研究进展

Research progress of sodium-glucose cotransporter-2 inhibitors in heart failure with preserved ejection fraction

钠-葡萄糖协同转运蛋白(sodium-glucose cotransporter,SGLT)-2抑制剂是一种新型的口服降糖药物。其作用不依赖胰岛素,而是通过抑制近曲小管葡萄糖重吸收而使葡萄糖从尿液排出,从而降低血糖。SGLT-2抑制剂不仅有降糖作用,而且在心血管疾病中获益明显,此药具有渗透性利尿、减轻容量负荷、改善心室重塑等优点。SGLT-2抑制剂能改善射血分数保留性心力衰竭(heart failure with preserved ejection fraction,HFpEF)患者的舒张功能,并降低心血管不良事件的发生风险。SGLT-2抑制剂应用于HFpEF患者可以使患者获益。因此,该文将探讨SGLT-2抑制剂在HFpEF中的研究进展。

Sodium-glucose cotransporter(SGLT)-2 inhibitors is a new type of oral sugar-lowering drug.Instead of relying on insulin,it lowers blood sugar by inhibiting the reabsorption of near-curvy tube glucose,which is drained from the urine.SGLT-2 inhibitors not only have a sugar-lowering effect,but also benefit significantly in cardiovascular disease,and this drug has the advantages of permeable diuretic,reducing capacity load,and improving ventricular remodeling.SGLT-2 inhibitors can improve the diastolic function of patients with heart failure with preserved ejection fraction(HFpEF)and reduce the risk of adverse cardiovascular events.SGLT-2 inhibitors can benefit patients with HFpEF.Therefore,this article will discuss the progress of SGLT-2 inhibitors in HFpEF.